A detailed history of Birchview Capital, LP transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 82,000 shares of CHRS stock, worth $68,880. This represents 0.1% of its overall portfolio holdings.

Number of Shares
82,000
Previous 372,000 77.96%
Holding current value
$68,880
Previous $386,000 70.73%
% of portfolio
0.1%
Previous 0.36%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$0.67 - $1.71 $194,300 - $495,900
-290,000 Reduced 77.96%
82,000 $113,000
Q3 2024

Nov 14, 2024

BUY
$0.99 - $1.8 $100,980 - $183,600
102,000 Added 37.78%
372,000 $386,000
Q1 2024

May 14, 2024

BUY
$2.02 - $3.14 $545,400 - $847,800
270,000 New
270,000 $645,000

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $65.3M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Birchview Capital, LP Portfolio

Follow Birchview Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Birchview Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Birchview Capital, LP with notifications on news.